Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria

American Journal of Respiratory and Critical Care Medicine

Volumn 195, Issue 1, 2017, Pages 78-85

  Raghu, Ganesh ^a   Wells, Athol U ^b   Nicholson, Andrew G ^b   Richeldi, Luca ^c   Flaherty, Kevin R ^d   Maulf, Florence Le ^e   Stowasser, Susanne ^f   Schlenker Herceg, Rozsa ^g   Hansell, David M ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e BOEHRINGER INGELHEIM   (France)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^g BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Diagnosis; High resolution computed tomography; Honeycombing; HRCT; Traction bronchiectasis

Indexed keywords

NINTEDANIB; PLACEBO; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE;

ABDOMINAL PAIN; AGED; ARTICLE; BRONCHIECTASIS; BRONCHITIS; CLINICAL TRIAL (TOPIC); COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG MECHANISM; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL PNEUMONIA; LUNG BIOPSY; MAJOR CLINICAL STUDY; MALE; NAUSEA; POST HOC ANALYSIS; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TRACTION BRONCHIECTASIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BIOPSY; DIAGNOSTIC IMAGING; IDIOPATHIC PULMONARY FIBROSIS; LUNG; PATHOLOGY; TREATMENT OUTCOME; X-RAY COMPUTED TOMOGRAPHY;

AGED; BIOPSY; DISEASE PROGRESSION; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; LUNG; MALE; PROTEIN-TYROSINE KINASES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 85008698220     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201602-0402OC     Document Type: Article

References (22)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
2. Flaherty KR, Andrei AC, King TE Jr, Raghu G, Colby TV, Wells A, Bassily N, Brown K, du Bois R, Flint A, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med 2007;175:1054-1060.
3. Flaherty KR, King TE Jr, Raghu G, Lynch JP III, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 2004;170:904-910.
4. Kreider ME, Hansen-Flaschen J, Ahmad NN, Rossman MD, Kaiser LR, Kucharczuk JC, Shrager JB. Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease. Ann Thorac Surg 2007;83:1140-1144.
5. Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, Elicker BM, Koth LL, King TE Jr, Wolters PJ, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2013; 42:750-757.
6. HuieTJ, Brown KK. Definitions of disease: should possible and probable idiopathic pulmonary fibrosis be enrolled in treatment trials? Respir Investig 2015;53:88-92.
7. Hansell DM, Goldin JG, King TE Jr, Lynch DA, Richeldi L, Wells AU. CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society. Lancet Respir Med 2015;3:483-496.
8. Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434-1445.
9. Boehringer Ingelheim Pharmaceuticals, Inc. OFEV (nintedanib) prescribing information. 2016 [accessed 2016 Apr 15]. Available from http://bidocs. boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser? docBase=renetnt&folderPath=/Prescribing + Informiation/PIs/Ofev/ofev.pclf
10. Boehringer Ingelheim. OFEV (nintedanib). Summary of product characteristics. 2016 [accessed 2016 Apr 18]. Available from http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/003821/WC500182474.pdf
11. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, et al.; American Thoracic Society; European Respiratory Society; Japanese Respiratory Society; Latin American Thoracic Association. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015;192:e3-e19.
12. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al.; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071-2082.
13. Raghu G, Wells A, Nicholson AG, Richeldi L, Flaherty KR, Le Maulf F, Stowasser S, Schlenker-Herceg R, Hansell DM. Consistent effect of nintedanib on decline in FVC in patients across subgroups based on HRCT diagnostic criteria: results from the INPULSIS trials in IPF [abstract]. Am J Respir Crit Care Med 2015; 191:A1022.
14. Lynch DA, Godwin JD, Safrin S, Starko KM, Hormel P, Brown KK, Raghu G, King TE Jr, Bradford WZ, Schwartz DA, et al.; Idiopathic Pulmonary Fibrosis Study Group. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med 2005;172:488-493.
15. Lee JW, Shehu E, Gjonbrataj J, Bahn YE, Rho BH, Lee MY, Choi WI. Clinical findings and outcomes in patients with possible usual interstitial pneumonia. Respir Med 2015;109:510-516.
16. Sverzellati N, Lynch DA, Hansell DM, Johkoh T, King TE Jr, Travis WD. American Thoracic Society-European Respiratory Society classification of the idiopathic interstitial pneumonias: advances in knowledge since 2002. Radiographies 2015;35:1849-1871.
17. Jacob J, Hansell DM. HRCT of fibrosing lung disease. Respirology 2015;20:859-872.
18. Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, Andreas S, Claussen M, Grohe C, Wilkens H, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J 2015;46:186-196.
19. Walsh SL, Sverzellati N, Devaraj A, Keir GJ, Wells AU, Hansell DM. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax 2014;69:216-222.
20. Watadani T, Sakai F, Johkoh T, Noma S, Akira M, Fujimoto K, Bankier AA, Lee KS, Muller NL, Song JW, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology 2013;266: 936-944.
21. Walsh SL, Calandriello L, Sverzellati N, Wells AU, Hansell DM; UIP Observer Consort. Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. Thorax 2016;71: 45-51.
22. Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J 2015;46:1113-1130.